Stockreport

Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Fractyl Health, Inc.  (GUTS) 
PDF Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026 Received favorable FDA feedback on De Novo classification request; De [Read more]